MY6900026A - Pyrazinoylguanidine derivatives - Google Patents

Pyrazinoylguanidine derivatives

Info

Publication number
MY6900026A
MY6900026A MY196926A MY6900026A MY6900026A MY 6900026 A MY6900026 A MY 6900026A MY 196926 A MY196926 A MY 196926A MY 6900026 A MY6900026 A MY 6900026A MY 6900026 A MY6900026 A MY 6900026A
Authority
MY
Malaysia
Prior art keywords
pyrazinoylguanidine
derivatives
pyrazinoylguanidine derivatives
Prior art date
Application number
MY196926A
Other languages
English (en)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of MY6900026A publication Critical patent/MY6900026A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MY196926A 1962-10-30 1969-12-31 Pyrazinoylguanidine derivatives MY6900026A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23423062A 1962-10-30 1962-10-30
US313315A US3313813A (en) 1962-10-30 1963-10-07 (3-amino-5, 6-disubstituted-pyrazinoyl) guanidines

Publications (1)

Publication Number Publication Date
MY6900026A true MY6900026A (en) 1969-12-31

Family

ID=26927694

Family Applications (1)

Application Number Title Priority Date Filing Date
MY196926A MY6900026A (en) 1962-10-30 1969-12-31 Pyrazinoylguanidine derivatives

Country Status (13)

Country Link
US (1) US3313813A (lt)
BE (1) BE639386A (lt)
BR (1) BR6354164D0 (lt)
CH (1) CH465617A (lt)
CY (1) CY440A (lt)
DE (2) DE1470053A1 (lt)
DK (4) DK114978B (lt)
FI (1) FI47102C (lt)
FR (1) FR1563612A (lt)
GB (1) GB1066855A (lt)
MY (1) MY6900026A (lt)
NL (2) NL142413B (lt)
SE (1) SE321230B (lt)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6409714A (lt) * 1962-10-30 1965-10-01
US3472848A (en) * 1966-11-17 1969-10-14 Merck & Co Inc 3-hydroxy and 3-mercapto-pyrazinoyl-guanidines,corresponding ethers and thioethers and processes for their preparation
US3948895A (en) * 1971-09-28 1976-04-06 E. I. Du Pont De Nemours And Company Synthesis of 3,5-diaminopyrazinoic acid from 3,5-diamino-2,6-dicyanopyrazine and intermediates
US4085211A (en) * 1975-12-15 1978-04-18 Merck & Co., Inc. Pyrazinecarboxamides and processes for preparing same
US4087526A (en) * 1976-07-23 1978-05-02 Merck & Co., Inc. (3-Amino-5-substituted-6-fluoropyrazinoyl or pyrazamido)-guanidines and their derivatives bearing substituents on the guanidino nitrogens
US4208413A (en) * 1977-03-04 1980-06-17 Merck & Co., Inc. N-Pyrazinecarbonyl-N'-alkoxycarbonyl and N',N"-bis(alkoxycarbonyl)guanidines and processes for preparing same
US4108859A (en) * 1977-06-06 1978-08-22 The Dow Chemical Company Microbicidal (pyridinylamino) alkyl guanidines
US4140776A (en) * 1977-09-16 1979-02-20 Merck & Co., Inc. N-pyrazinecarbonyl-N'-acylguanidines
US4190655A (en) * 1978-08-28 1980-02-26 Merck & Co., Inc. Amiloride citrate
EP0009054A1 (en) * 1978-09-19 1980-04-02 Merck & Co. Inc. N-Pyrazinecarbonyl-N'-substituted-sulfamoyl-guanidine and processes for preparing same
US4224447A (en) * 1979-03-27 1980-09-23 Merck & Co., Inc. Novel pyrazinecarboxamides and processes for preparing same
US4246406A (en) * 1979-03-27 1981-01-20 Merck & Co., Inc. Heterocyclic substituted pyrazinoylguanidines
US4362724A (en) * 1980-05-19 1982-12-07 Merck & Co., Inc. Method of treating edema and hypertension and pharmaceutical composition therefor in which the active ingredient comprises a novel substituted pyrazinyl-1,2,4-oxadiazole and a kaliuretic diuretic
US4309540A (en) * 1980-05-19 1982-01-05 Merck & Co., Inc. Substituted pyrazinyl-1,2,4-oxadiazoles
US4454132A (en) * 1981-03-16 1984-06-12 Merck & Co., Inc. Pharmaceutical compositions of novel substituted pyrazinyl-1,2,4-oxadiazoles useful in the treatment of edema and hypertension
US4510322A (en) * 1981-07-13 1985-04-09 Merck & Co., Inc. Indacrinone having enhanced uricosuric
US4952582A (en) * 1982-01-04 1990-08-28 Beyer Jr Karl H Pyrazinoylguanidine and derivatives thereof having few polar substituents and being useful as hyperuretic agents
US4663322A (en) * 1982-01-04 1987-05-05 Beyer Jr Karl H Antihypertensive hyperuretic and saluretic agent combinations
DE3312516A1 (de) * 1983-04-07 1984-10-11 Brigitte Dr. 7400 Tübingen Pfeiffer Kernsubstituierte phenylalkylenguanidinderivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
US4604394A (en) * 1984-10-01 1986-08-05 Merck & Co., Inc. Antiarrhythmic compositions and method
DE3925847A1 (de) * 1989-08-04 1991-02-07 Huels Chemische Werke Ag Verfahren zur herstellung von 3-aminopyrazin-2-carbonsaeuremethylester
AU654979B2 (en) * 1990-10-05 1994-12-01 University Of North Carolina At Chapel Hill, The Method of administering amiloride
US5304125A (en) * 1990-10-05 1994-04-19 The University Of North Carolina Apparatus for administering solid particulate aerosols to the lungs
TW213903B (lt) * 1991-08-16 1993-10-01 Boehringer Ingelheim Kg
US6169107B1 (en) 1993-04-28 2001-01-02 Sumitomo Pharmaceutical Co., Ltd. Indoloylguanidine derivatives
DE4337609A1 (de) * 1993-11-04 1995-05-11 Boehringer Ingelheim Kg Neue Pyrazincarboxamidderivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
US5656256A (en) * 1994-12-14 1997-08-12 The University Of North Carolina At Chapel Hill Methods of treating lung disease by an aerosol containing benzamil or phenamil
TW372967B (en) * 1994-12-27 1999-11-01 Kanebo Ltd 1,4 benzoxazine derivative, pharmaceutical composition containing the same and use thereof
US5635160A (en) 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US5628984A (en) 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
US5801177A (en) * 1995-12-14 1998-09-01 Beyer, Jr.; Karl H. Method for controlling and/or lowering serum glucose and fatty acid concentrations and hypertensive blood pressure in non-insulin-dependent diabetic patients
US5877217A (en) * 1995-12-26 1999-03-02 Alteon Inc. N-acylaminoalkyl-hydrazinecarboximidamides
ATE288273T1 (de) * 1997-08-29 2005-02-15 Univ North Carolina Verwendung von uridin-5'-diphosphat und analoge zur behandlung von lungenerkrankungen
US6264975B1 (en) 1998-10-20 2001-07-24 The University Of North Carolina At Chapel Hill Methods of hydrating mucosal surfaces
CA2360687A1 (en) * 1999-01-29 2000-08-03 Karl H. Beyer, Jr. (Deceased) Composition and method for treating diabetes
US6475509B1 (en) 1999-07-19 2002-11-05 The University Of North Carolina At Chapel Hill Covalent conjugates of sodium channel blockers and active compounds
KR100656716B1 (ko) 2000-11-21 2006-12-13 상꾜 가부시키가이샤 의약 조성물
US6858614B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenolic guanidine sodium channel blockers
US6858615B2 (en) * 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US7704995B2 (en) * 2002-05-03 2010-04-27 Exelixis, Inc. Protein kinase modulators and methods of use
WO2003093297A2 (en) * 2002-05-03 2003-11-13 Exelixis, Inc. Protein kinase modulators and methods of use
AP2005003232A0 (en) 2002-08-19 2005-03-31 Pfizer Prod Inc Combination therapy for hyperproliferative diseases.
US6903105B2 (en) * 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
KR101153254B1 (ko) 2003-06-26 2012-07-02 바이오트론 리미티드 항바이러스 화합물 및 방법
AU2004248859C1 (en) * 2003-06-26 2011-11-24 Biotron Limited Antiviral acylguanidine compounds and methods
US7326706B2 (en) * 2003-08-15 2008-02-05 Bristol-Myers Squibb Company Pyrazine modulators of cannabinoid receptors
PT1663235E (pt) 2003-08-18 2013-10-29 Parion Sciences Inc Novos bloqueadores dos canais do sódio de pirazinoílguanidina protegida
JP2007502827A (ja) * 2003-08-18 2007-02-15 パリオン・サイエンシィズ・インコーポレーテッド 脂肪族ピラジノイルグアニジンナトリウムチャネルブロッカー
US20050090505A1 (en) * 2003-08-18 2005-04-28 Johnson Michael R. Methods of reducing risk of infection from pathogens
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
US20090253714A1 (en) * 2003-08-20 2009-10-08 Johnson Michael R Methods of reducing risk of infection from pathogens
US20070099968A1 (en) * 2004-06-26 2007-05-03 Biotron Limited Antiviral compounds and methods
US20070021439A1 (en) * 2005-07-25 2007-01-25 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
EP1962892A4 (en) * 2005-11-22 2011-10-12 Univ South Florida INHIBITION OF CELL PROLIFERATION
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
ES2382009T3 (es) 2006-12-01 2012-06-04 Bristol-Myers Squibb Company Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares
EP2211956A4 (en) 2007-10-10 2014-07-09 Parion Sciences Inc DISPOSAL OF OSMOLYTES WITH A NOSE CANNULA
NZ586940A (en) * 2008-02-26 2012-08-31 Parion Sciences Inc Poly aromatic sodium channel blocker compounds comprising both pyrazine and guanidine moieties
DE102008053024B4 (de) 2008-10-24 2015-04-30 RUHR-UNIVERSITäT BOCHUM Verwendung von Amilorid-Derivaten zur Bekämpfung von Insekten und Milben
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
US9072738B2 (en) 2011-06-27 2015-07-07 Parion Sciences, Inc. Chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
TR201809148T4 (tr) 2012-05-29 2018-07-23 Parion Sciences Inc Göz kuruluğu ve diğer mukozal hastalıkların tedavisi için sodyum kanal blokör etkinliğine sahip dendrimer benzeri amino asitler.
KR20150095870A (ko) 2012-12-17 2015-08-21 패리온 사이언스 인코퍼레이티드 3,5-디아미노-6-클로로-n-(n-(4-페닐부틸)카르밤이미도일)피라진-2-카르복스아미드 화합물
AU2013363218B2 (en) 2012-12-17 2018-03-15 Parion Sciences, Inc. Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration
CN105143203A (zh) 2013-04-17 2015-12-09 辉瑞大药厂 用于治疗心血管疾病的n-哌啶-3-基苯甲酰胺衍生物
JP6449870B2 (ja) * 2013-07-08 2019-01-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肺および気道の疾患を処置するための上皮性ナトリウムチャネルの阻害剤としてのアミロライド型化合物
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
BR112018076800A2 (pt) * 2016-07-29 2019-04-02 Toray Industries, Inc. derivado de guanidina, medicamento, inibidor da proteína 1 da translocação de linfoma de tecido linfóide associado com mucosa, e, agente terapêutico ou profilático.
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE639393A (lt) * 1962-10-30

Also Published As

Publication number Publication date
DK114557B (da) 1969-07-14
BR6354164D0 (pt) 1973-09-18
DE1470053A1 (de) 1969-06-26
NL299931A (lt)
CH465617A (de) 1968-11-30
DK114978B (da) 1969-08-25
DK116943B (da) 1970-03-02
DK115403B (da) 1969-10-06
BE639386A (lt)
SE321230B (lt) 1970-03-02
NL142413B (nl) 1974-06-17
CY440A (en) 1968-05-18
FR1563612A (lt) 1969-04-18
FI47102B (lt) 1973-05-31
DE1795438B1 (de) 1973-09-06
FI47102C (fi) 1973-09-10
US3313813A (en) 1967-04-11
DE1795438C2 (de) 1974-04-11
GB1066855A (en) 1967-04-26

Similar Documents

Publication Publication Date Title
MY6900026A (en) Pyrazinoylguanidine derivatives
MY6700139A (en) New nitrofuran derivatives
CA651682A (en) Pyrido-triazole derivatives
IE26887L (en) Butanetetrol derivatives
IE26552L (en) Aminohydantoin derivatives
IE26905L (en) Benzodiazepinthione derivatives
IE26949L (en) Benzenesulphonyl-urea derivatives
IE26435L (en) Dibenzoazepine derivatives
IE26511L (en) Aryl-propionyl-piperidine derivatives
IE26360L (en) Piperazine derivatives
IE27037L (en) Azathioxanthene derivatives.
AU279453B2 (en) Lumiergoline derivatives
AU266725B2 (en) Azathioxanthene derivatives
AU275529B2 (en) Benzoisothiazolone derivatives
AU272292B2 (en) Quinaldinium derivatives
AU269605B2 (en) Benzimidazolinone derivatives
AU269213B2 (en) 5-chloropyridazone derivatives
IE26664L (en) Pyrimidine derivatives
IE26663L (en) Pyrimidine derivatives
AU282006B2 (en) Heterocyclic derivatives
AU265165B2 (en) Melamine derivatives
IE26553L (en) Nitrofuran derivatives
IE27126L (en) Nitrofuran derivatives
IE27128L (en) Nitrofuran derivatives
IE27100L (en) Nitrofuran derivatives